1. Programmed death-1 blockade in mismatch repair deficient colorectal cancer
- Author
-
Daniel A. Laheru, Dung T. Le, Todd S. Crocenzi, Jennifer N. Uram, Luis A. Diaz, Tim F. Greten, Richard M. Goldberg, Soonmo Peter Kang, Bjarne Bartlett, Bert Vogelstein, James R. Eshleman, Holly Kemberling, James J. Lee, George A. Fisher, Aleksandra Eyring, Hao Wang, Ross C. Donehower, Minori Koshiji, Nilofer S. Azad, and Robert A. Anders
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,biology ,business.industry ,Colorectal cancer ,Phases of clinical research ,Pembrolizumab ,medicine.disease ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,Cohort ,Immunology ,medicine ,biology.protein ,DNA mismatch repair ,Antibody ,business ,Survival rate ,CD8 - Abstract
103Background: Mismatch repair deficient (dMMR) colon cancers are densely infiltrated with CD8+T cells and regress when treated with anti-programmed death-1 (PD-1) antibodies. This anti-tumor response is thought to be potentiated by the thousands of somatic mutations that when expressed as proteins result in hundreds of potentially immunogenic neo-antigens that can be recognized by the patient’s immune system. Methods: We previously reported a phase 2 study to evaluate the activity of pembrolizumab (pembro), a PD-1 antibody in treatment refractory dMMR colon cancers (NEJM 2015). We are reporting the expanded trial and updated data for the mismatch repair deficient CRC (dMMR, cohort A) and mismatch repair proficient CRC (pMMR, cohort B) cohorts. Pembro was administered at 10 mg/kg every 14 days in patients with 2 or more prior therapies. The co-primary endpoints were response and progression-free survival rate at 20 weeks. Secondary endpoints included disease control rate (DCR = CR + PR + SD), progression ...
- Published
- 2016
- Full Text
- View/download PDF